Dr. Reddy’s issued a voluntary recall of six lots of sapropterin dihydrochloride powder used to treat phenylketonuria (PKU) due to potential potency issues following internal testing and customer ...

Dr. Reddy’s Laboratories (NYSE:RDY) disclosed in a filing that it has bought a 6.46% stake in Edity Therapeutics. According to an SEC filing, the Indian drugmaker bought approximately 1M preferred A-1 ...

Dr. Reddy’s Laboratories share price jumped over 4% on Thursday amid string buying momentum. Dr. Reddy’s shares rallied as much as 4.09% to ₹1,303.45 apiece on the BSE. Life Insurance Corporation of ...

While drugmaker Dr Reddy's Laboratories' Q3 earnings were slightly above the Street's estimates, the highlight of the show was declining revenue contribution from Revlimid, which also weighed on ...

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), announced ...

Nitish Kumar Reddy became the third youngest Indian batter to score a century in Australia during the third day of the Boxing Day Test against Australia at the Melbourne Cricket Ground. At the end of ...

Pharmaceutical layoffs planned? No, says Dr Reddy's Laboratories, as the drugmaker categorically denied media reports that has undertaken workforce reduction to cut costs by around 25 per cent.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...